Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
151.2 USD | +2.59% | -0.10% | -21.00% |
Financials (USD)
Sales 2024 * | 1.87B | Sales 2025 * | 2.26B | Capitalization | 19.13B |
---|---|---|---|---|---|
Net income 2024 * | -451M | Net income 2025 * | -257M | EV / Sales 2024 * | 9.54 x |
Net cash position 2024 * | 1.26B | Net cash position 2025 * | 475M | EV / Sales 2025 * | 8.26 x |
P/E ratio 2024 * |
-42.8
x | P/E ratio 2025 * |
-81.2
x | Employees | 2,100 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.59% |
Latest transcript on Alnylam Pharmaceuticals, Inc.
1 day | +2.59% | ||
1 week | -0.10% | ||
Current month | +5.05% | ||
1 month | +3.07% | ||
3 months | +2.87% | ||
6 months | -10.50% | ||
Current year | -21.00% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 61 | 16-09-18 | |
Jeffrey Poulton
DFI | Director of Finance/CFO | 56 | 19-08-12 |
Piyush Sharma
CMP | Compliance Officer | - | 22-09-20 |
Members of the board | Title | Age | Since |
---|---|---|---|
David Pyott
BRD | Director/Board Member | 70 | 15-12-17 |
Charles Sigal
BRD | Director/Board Member | 72 | 22-08-21 |
Margaret Hamburg
BRD | Director/Board Member | 68 | 19-01-09 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
5.08% | 1 M€ | +0.15% | - | |
4.04% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-16 | 151.2 | +2.59% | 934,860 |
24-05-15 | 147.4 | -0.33% | 536,143 |
24-05-14 | 147.9 | -1.33% | 604,966 |
24-05-13 | 149.9 | -0.39% | 512,792 |
24-05-10 | 150.5 | -0.59% | 322,795 |
Delayed Quote Nasdaq, May 16, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-21.00% | 19.13B | |
+33.37% | 50.85B | |
+1.55% | 42.82B | |
+49.17% | 42.03B | |
-4.22% | 29.55B | |
+11.57% | 26.11B | |
+7.36% | 13.05B | |
+28.30% | 12.16B | |
+23.80% | 12.08B | |
-4.93% | 11.58B |
- Stock Market
- Equities
- ALNY Stock